Key Takeaways
- Myriad Genetics, Inc. (NASDAQ: MYGN) appointed Raj Jampa as Chief Technology Officer, effective June 1, 2026.
- CEO Sam Raha highlighted Jampa’s vision and execution experience as critical to scaling the company’s technology foundation, improving customer experience, and driving growth.
- Jampa expressed enthusiasm for modernizing Myriad’s tech infrastructure, expanding data and AI capabilities, and delivering impactful solutions for patients, providers, and the business.
- Prior to Myriad, Jampa held senior technology leadership positions at Agilent Technologies, Exact Sciences, and Genomic Health, where he led large‑scale transformations of enterprise platforms, digital capabilities, and operating models.
- Myriad Genetics continues to focus on molecular diagnostic and precision‑medicine tests that uncover genetic insights, guide treatment decisions, and aim to lower healthcare costs.
- The press release includes a Safe Harbor statement cautioning that forward‑looking statements are subject to risks and uncertainties detailed in the company’s SEC filings.
- Investor relations contact: Matt Scalo, (801) 584‑3532, [email protected].
Appointment of Raj Jampa as Chief Technology Officer
Myriad Genetics, Inc. announced on June 2, 2026 that Raj Jampa has been named the company’s Chief Technology Officer, with the role taking effect June 1, 2026. The appointment underscores Myriad’s commitment to strengthening its technological leadership as it pursues the next phase of growth and value creation in the precision‑medicine arena.
CEO’s Endorsement of Jampa’s Vision and Execution Skills
Sam Raha, Chief Executive Officer of Myriad Genetics, praised Jampa as a “proven technology leader with the vision and execution experience to help scale our business and accelerate technology innovation across the enterprise.” Raha emphasized that Jampa’s leadership will be instrumental in fortifying Myriad’s digital technology foundation, enhancing the customer experience, and supporting sustained growth.
Jampa’s Statement on Joining Myriad at a Pivotal Moment
In his own remarks, Raj Jampa expressed honor at joining Myriad during what he described as an “important time in its growth.” He conveyed his eagerness to collaborate across the organization to modernize the technology foundation, scale data and artificial‑intelligence (AI) capabilities, and deliver solutions that create meaningful impact for patients, providers, and the business alike.
Jampa’s Extensive Background in Technology Leadership
Before his move to Myriad, Jampa held senior technology leadership roles at Agilent Technologies, Exact Sciences, and Genomic Health. At these companies he spearheaded large‑scale transformation initiatives that overhauled enterprise platforms, upgraded digital capabilities, and redefined operating models. His track record of modernizing technology infrastructure and scaling AI‑enabled systems positions him well to advance Myriad’s strategic objectives.
Strategic Focus on AI and Digital Transformation
As CTO, Jampa will oversee the strategy and execution of Myriad’s technology organization, with a particular emphasis on leveraging AI to drive increased efficiency and effectiveness. This focus aligns with industry trends where AI‑driven analytics are increasingly used to interpret complex genetic data, accelerate test development, and personalize patient care pathways.
Overview of Myriad Genetics’ Mission and Offerings
Myriad Genetics is a leading molecular diagnostic and precision‑medicine company dedicated to advancing health and well‑being for all. The firm develops and commercializes molecular tests that reveal genetic insights, assess disease risk or progression, and guide treatment decisions across numerous medical specialties. By enabling earlier detection and more precise therapies, Myriad aims to improve patient outcomes while contributing to lower overall healthcare costs.
Safe Harbor Statement Regarding Forward‑Looking Information
The press release contains a Safe Harbor notice clarifying that statements about Jampa’s impact on Myriad’s digital foundation, customer experience, and growth are forward‑looking under the Private Securities Litigation Reform Act of 1995. Such statements reflect management’s current expectations and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially. Factors include those detailed in Myriad’s SEC filings, including the Annual Report on Form 10‑K filed February 24, 2026, and subsequent updates in quarterly or current reports. The company disclaims any obligation to update these statements except as required by law.
Investor Relations Contact Information
For further inquiries, investors and media may contact Matt Scalo at (801) 584‑3532 or via email at [email protected]. This contact point serves as the primary channel for questions regarding the announcement, financial performance, or other corporate matters.